Chongkundang
Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. Chong Kun Dang Holdings Corp. was founded in 1941 and is based in Seoul, South Korea.
Chongkundang (001630) - Net Assets
Latest net assets as of September 2025: ₩885.50 Billion KRW
Based on the latest financial reports, Chongkundang (001630) has net assets worth ₩885.50 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.60 Trillion) and total liabilities (₩713.67 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩885.50 Billion |
| % of Total Assets | 55.37% |
| Annual Growth Rate | 5.71% |
| 5-Year Change | 1.13% |
| 10-Year Change | 122.9% |
| Growth Volatility | 27.26 |
Chongkundang - Net Assets Trend (2000–2024)
This chart illustrates how Chongkundang's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chongkundang (2000–2024)
The table below shows the annual net assets of Chongkundang from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩849.77 Billion | +3.19% |
| 2023-12-31 | ₩823.48 Billion | +3.12% |
| 2022-12-31 | ₩798.54 Billion | -4.93% |
| 2021-12-31 | ₩839.97 Billion | -0.04% |
| 2020-12-31 | ₩840.30 Billion | +13.54% |
| 2019-12-31 | ₩740.07 Billion | +10.33% |
| 2018-12-31 | ₩670.78 Billion | +4.78% |
| 2017-12-31 | ₩640.19 Billion | +16.82% |
| 2016-12-31 | ₩548.02 Billion | +43.75% |
| 2015-12-31 | ₩381.24 Billion | +102.29% |
| 2014-12-31 | ₩188.47 Billion | +1.71% |
| 2013-12-31 | ₩185.30 Billion | -51.83% |
| 2012-12-31 | ₩384.65 Billion | +7.06% |
| 2011-12-31 | ₩359.28 Billion | +32.53% |
| 2010-12-31 | ₩271.09 Billion | +19.00% |
| 2009-12-31 | ₩227.80 Billion | +12.10% |
| 2008-12-31 | ₩203.21 Billion | +12.53% |
| 2007-12-31 | ₩180.58 Billion | +11.61% |
| 2006-12-31 | ₩161.81 Billion | +15.74% |
| 2005-12-31 | ₩139.80 Billion | +12.16% |
| 2004-12-31 | ₩124.65 Billion | +11.95% |
| 2003-12-31 | ₩111.34 Billion | -3.80% |
| 2002-12-31 | ₩115.75 Billion | -34.66% |
| 2001-12-31 | ₩177.15 Billion | -20.98% |
| 2000-12-31 | ₩224.20 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chongkundang's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 42659656586000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩426.60 Billion | 72.61% |
| Other Components | ₩160.90 Billion | 27.39% |
| Total Equity | ₩587.50 Billion | 100.00% |
Chongkundang Competitors by Market Cap
The table below lists competitors of Chongkundang ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TEMC Co. Ltd.
KQ:425040
|
$78.16 Million |
|
ChampionsGate Acquisition Corp
NASDAQ:CHPGU
|
$78.17 Million |
|
VisionWave Holdings, Inc. Common Stock
NASDAQ:VWAV
|
$78.21 Million |
|
Evertop Wire Cable Corp
TW:1616
|
$78.22 Million |
|
Sidus Space Inc
NASDAQ:SIDU
|
$78.15 Million |
|
Americanas S.A.
SA:AMER3
|
$78.12 Million |
|
Iljin Power Co. Ltd
KQ:094820
|
$78.10 Million |
|
Bridger Aerospace Group Holdings, Inc. Common Stock
NASDAQ:BAER
|
$78.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chongkundang's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 562,950,342,280 to 587,498,486,050, a change of 24,548,143,770 (4.4%).
- Net income of 33,595,915,640 contributed positively to equity growth.
- Dividend payments of 12,973,128,400 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩33.60 Billion | +5.72% |
| Dividends Paid | ₩12.97 Billion | -2.21% |
| Other Changes | ₩3.93 Billion | +0.67% |
| Total Change | ₩- | 4.36% |
Book Value vs Market Value Analysis
This analysis compares Chongkundang's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.39x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.59x to 0.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩81621.70 | ₩48550.00 | x |
| 2018-12-31 | ₩85684.90 | ₩48550.00 | x |
| 2019-12-31 | ₩93600.12 | ₩48550.00 | x |
| 2020-12-31 | ₩108137.90 | ₩48550.00 | x |
| 2021-12-31 | ₩109358.48 | ₩48550.00 | x |
| 2022-12-31 | ₩108440.39 | ₩48550.00 | x |
| 2023-12-31 | ₩117949.70 | ₩48550.00 | x |
| 2024-12-31 | ₩123409.58 | ₩48550.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chongkundang utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.72%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.51%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 2.55x
- Recent ROE (5.72%) is below the historical average (20.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 1.59% | 1.33% | 0.46x | 2.63x | ₩-18.60 Billion |
| 2001 | 1.55% | 1.02% | 0.53x | 2.89x | ₩-14.26 Billion |
| 2003 | 9.67% | 3.59% | 0.62x | 4.33x | ₩-296.54 Million |
| 2004 | 14.40% | 6.83% | 0.70x | 3.03x | ₩4.83 Billion |
| 2005 | 18.63% | 8.84% | 0.79x | 2.67x | ₩11.54 Billion |
| 2006 | 14.40% | 7.31% | 0.78x | 2.54x | ₩6.87 Billion |
| 2007 | 11.36% | 6.27% | 0.77x | 2.36x | ₩2.38 Billion |
| 2008 | 11.07% | 5.67% | 0.85x | 2.30x | ₩2.08 Billion |
| 2009 | 11.71% | 5.68% | 0.98x | 2.10x | ₩3.76 Billion |
| 2010 | 17.10% | 8.40% | 0.95x | 2.14x | ₩18.37 Billion |
| 2011 | 15.84% | 9.40% | 0.84x | 2.00x | ₩19.74 Billion |
| 2012 | 8.93% | 5.38% | 0.84x | 1.98x | ₩-3.82 Billion |
| 2013 | 279.42% | 74.16% | 2.02x | 1.87x | ₩400.86 Billion |
| 2014 | 5.99% | 5.22% | 0.60x | 1.92x | ₩-6.34 Billion |
| 2015 | 5.19% | 6.86% | 0.44x | 1.71x | ₩-14.08 Billion |
| 2016 | 8.17% | 8.77% | 0.48x | 1.96x | ₩-6.60 Billion |
| 2017 | 11.74% | 10.65% | 0.55x | 2.00x | ₩7.12 Billion |
| 2018 | 6.40% | 5.17% | 0.61x | 2.03x | ₩-15.47 Billion |
| 2019 | 9.60% | 6.25% | 0.67x | 2.29x | ₩-1.86 Billion |
| 2020 | 14.57% | 9.17% | 0.68x | 2.33x | ₩24.66 Billion |
| 2021 | 2.96% | 1.73% | 0.68x | 2.53x | ₩-38.10 Billion |
| 2022 | 0.20% | 0.12% | 0.66x | 2.60x | ₩-51.81 Billion |
| 2023 | 8.35% | 5.34% | 0.60x | 2.59x | ₩-9.29 Billion |
| 2024 | 5.72% | 3.51% | 0.64x | 2.55x | ₩-25.15 Billion |
Industry Comparison
This section compares Chongkundang's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chongkundang (001630) | ₩885.50 Billion | 1.59% | 0.81x | $78.16 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |